scholarly journals Alterations in “in vivo” histology of retina in bilateral chronic central serous chorioretinopathy after intravitreal bevacizumab

2011 ◽  
Vol 4 (4) ◽  
pp. 137-140
Author(s):  
Sandeep Saxena ◽  
Astha Jain
Keyword(s):  
Central Serous Chorioretinopathy ◽  
Intravitreal Bevacizumab ◽  
Chronic Central Serous Chorioretinopathy

Results of One-Year Follow-Up Examinations after Intravitreal Bevacizumab Administration for Chronic Central Serous Chorioretinopathy

2011 ◽  
Vol 225 (1) ◽  
pp. 37-40 ◽  
Author(s):  
Maiko Inoue ◽  
Kazuaki Kadonosono ◽  
Yoichiro Watanabe ◽  
Satoshi Kobayashi ◽  
Shin Yamane ◽  
...  
Keyword(s):  
Central Serous Chorioretinopathy ◽  
Intravitreal Bevacizumab ◽  
Chronic Central Serous Chorioretinopathy ◽  
One Year

scholarly journals Assessment of choriocapillary blood flow changes in response to half-dose PDT in chronic central serous chorioretinopathy using OCTA

2020 ◽  
Author(s):  
Juejun Liu ◽  
Changzheng Chen ◽  
Lu Li ◽  
Yishuang Xu ◽  
Zuohuizi Yi ◽  
...  
Keyword(s):  
Blood Flow ◽  
Central Serous Chorioretinopathy ◽  
Early Stage ◽  
Early Response ◽  
Therapeutic Effects ◽  
Chronic Central Serous Chorioretinopathy ◽  
Half Dose ◽  
Flow Changes

Abstract Background: Optical coherence tomography angiography (OCTA) is a principally new imaging technique that provide quantitative method to analyze choriocapillaris (CC) flow changes, while assessment of CC in vivo could be valuable in understanding the pathological mechanism of chronic central serous chorioretinopathy (CCSC) and the therapeutic effects of photodynamic therapy (PDT). In this study, we sought to quantify blood flow changes in CC of CCSC patients receiving half-dose PDT using OCTA.Methods: A total of 28 affected eyes and 24 unaffected eyes of 26 CCSC patients receiving half-dose PDT, and 40 eyes of 20 healthy gender- and age-matched subjects were retrospectively enrolled. The proportion of total areas of flow signal voids (FSV, %) in CC level of OCTA was assessed in both eyes of the CCSC patients at baseline and repeated in multiple sections at 1-week, 1-month, 3-month and 6-month intervals after PDT. In addition, CC patterns in response to PDT at early stage and their subsequent morphologic changes were qualitatively documented using OCTA. Results: For affected eyes, significant decrease in FSV was found at 6-m follow-up when compared with that at 1-m follow-up (p=0.036). When compared to normal control eyes, FSV in affected eyes was significantly higher at 1-m, 3-m and 6-m follow-up (p<0.05 for all), while FSV in unaffected eyes was significantly higher at baseline, 1-w, 1-m and 3-m follow-up (p<0.05 for all). Three CC patterns of early response to PDT were identified, including signs of recovery with more even flow signals, transient appearance of worse ischemia and secondary neovascularization within CC level.Conclusion: Abnormal CC flow attenuation remains in completely resolved eyes of CCSC patients treated with half-dose PDT.

scholarly journals Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy

2019 ◽  
Vol 31 (4) ◽  
pp. 406-410
Author(s):  
Aliagha Alishiri ◽  
Khosrow Jadidi ◽  
Seyed Aliasghar Mosavi ◽  
Hamidreza Torabi
Keyword(s):  
Central Serous Chorioretinopathy ◽  
Intravitreal Bevacizumab ◽  
Chronic Central Serous Chorioretinopathy

scholarly journals Increase in Central Retinal Edema after Subthreshold Diode Micropulse Laser Treatment of Chronic Central Serous Chorioretinopathy

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Maciej Gawęcki
Keyword(s):  
Central Serous Chorioretinopathy ◽  
Fundus Autofluorescence ◽  
Subretinal Fluid ◽  
Intravitreal Bevacizumab ◽  
Thermal Reaction ◽  
Retinal Edema ◽  
Chronic Central Serous Chorioretinopathy ◽  
Intravitreal Bevacizumab Injection ◽  
Micropulse Laser

Purpose. Subthreshold diode micropulse laser (SDM) treatment is believed to be safe method of treating clinical entities involving retinal edema. We present a case of serous edematous reaction of the retina to SDM treatment.Methods. Case report.Results. A patient with chronic central serous chorioretinopathy (CSCR) was treated with SDM Yellow multispot laser. Procedure had been preceded by careful titration of the laser power, which after achieving of the threshold parameter was decreased by 50%. The follow-up visit two days after treatment revealed significant central retinal edema and subretinal fluid. Fundus autofluorescence image showed thermal reaction from the RPE in the form of small spots of hyperfluorescence corresponding to the laser multispot pattern used for treatment. Retinal edema resolved after topical bromfenac and single intravitreal bevacizumab injection. Slight pigmentary reaction from the RPE persisted.Conclusion. In the treatment of CSCR, there is a need to significantly reduce threshold SDM power parameters or simply use very low power without titration.

Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy

2012 ◽  
Vol 56 (6) ◽  
pp. 608-612 ◽  
Author(s):  
Francesco Semeraro ◽  
Mario R. Romano ◽  
Paola Danzi ◽  
Francesco Morescalchi ◽  
Ciro Costagliola
Keyword(s):  
Photodynamic Therapy ◽  
Central Serous Chorioretinopathy ◽  
Intravitreal Bevacizumab ◽  
Chronic Central Serous Chorioretinopathy

Intravitreal Bevacizumab for Treatment of Chronic Central Serous Chorioretinopathy

2009 ◽  
Vol 19 (4) ◽  
pp. 613-617 ◽  
Author(s):  
Karen B. Schaal ◽  
Alexandra E. Hoeh ◽  
Alexander Scheuerle ◽  
Florian Schuett ◽  
Stefan Dithmar
Keyword(s):  
Repeated Measures ◽  
Central Serous Chorioretinopathy ◽  
Retinal Thickness ◽  
Statistical Significance ◽  
Subretinal Fluid ◽  
Intravitreal Bevacizumab ◽  
Intravitreal Injections ◽  
Central Retinal Thickness ◽  
Chronic Central Serous Chorioretinopathy

Purpose To evaluate the short-term safety and efficacy of intravitreal bevacizumab for the treatment of intraretinal or subretinal fluid accumulation secondary to chronic central serous chorioretinopathy (CSC). Methods Twelve patients were treated with intravitreal injections of 2.5 mg bevacizumab at 6-to 8-week intervals until intraretinal or subretinal fluid resolved. Observation procedures were Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), ophthalmic examination, and optical coherence tomography (OCT), performed at 6- to 8-week intervals. Fluorescein angiography was performed at baseline visit and thereafter depending on clinical and OCT findings. Multivariate analysis of variance with repeated measures was used to calculate a statistical significance of change in BCVA and mean central retinal thickness, which were the main outcome measures. SAS statistical software was used for analyses. Results Patients received 2±1 intravitreal injections of bevacizumab on average during a follow-up of 24±14 weeks. Mean BCVA increased by 2±2 lines; the change in BCVA (log-MAR) was significant (p<0.02). Mean central retinal thickness decreased significantly over follow-up (p<0.05), with 6 patients (50%) showing complete resolution of subretinal fluid. Conclusions Anatomic and functional improvement following intravitreal bevacizumab injections suggest that vascular endothelial growth factor (VEGF) may be involved in fluid leakage in patients with chronic CSC. The results suggest a possible role for anti-VEGF agents in the treatment of chronic CSC. Further evaluation of intravitreal bevacizumab for chronic CSC in controlled randomized studies is warranted.

Sign in / Sign up

Export Citation Format

Share Document